Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy

This article was originally published in The Pink Sheet Daily

Executive Summary

Through a licensing agreement, VentiRx gains rights to Array’s TLR program containing several development candidates

You may also be interested in...



Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer

VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.

Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets

Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.

Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets

Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS065745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel